Gilead Sciences’ SWOT analysis: biotech giant faces HIV funding headwinds

Gilead Sciences (NASDAQ:GILD), a prominent player in the biopharmaceutical industry with a market capitalization of $139 billion, finds itself at a crossroads as it navigates challenges in its core HIV franchise while pursuing growth opportunities in oncology. The company, known for its innovative therapeutics in virology and oncology, has recently faced a series of developments that have caught the attention of investors and analysts alike. According to InvestingPro data, GILD has demonstrated remarkable stability with low price volatility and impressive year-to-date returns of 24%.

Financial Performance and Market Position

Gilead’s recent financial performance has been a mixed bag. In its latest earnings report, the company missed revenue estimates but managed to beat expectations on earnings per share (EPS) of $5.01. With robust gross profit margins of 78.5% and strong cash flows sufficient to cover interest payments, Gilead maintains a solid financial foundation. Despite the revenue shortfall, Gilead maintained its guidance for both revenue and earnings, suggesting a degree of confidence in its near-term outlook. The market reacted negatively to the news, with shares falling by 3% following the announcement. Based on InvestingPro’s Fair Value analysis, GILD currently appears undervalued, presenting a potential opportunity for investors. For detailed valuation metrics and 8 additional exclusive ProTips, visit InvestingPro.

As of August 20, 2025, Gilead’s stock price stood at $118.73, reflecting its status as a large-cap stock within the biotechnology sector. With a P/E ratio of 22.4x and strong return on equity of 33%, the company demonstrates solid fundamentals. Analysts note that Gilead trades at a discount compared to its large-cap peers, which could present an opportunity for multiple expansion as the company continues to derisk its oncology franchise. Want to discover if GILD is among the market’s most promising opportunities? Check out our undervalued stocks list and comprehensive Pro Research Report, available exclusively on InvestingPro.

HIV Franchise: Challenges and Opportunities

Gilead’s HIV franchise, long a cornerstone of the company’s success, faces new challenges. Recent reports suggest potential cuts to Health and Human Services (HHS) funding for domestic HIV prevention, which could impact Gilead’s Pre-Exposure Prophylaxis (PrEP) franchise. While the potential removal of approximately $1.3 billion in Centers for Disease Control and Prevention (CDC) funding is seen as a modest headwind rather than a significant threat, it has raised concerns among investors.

Despite these challenges, Gilead remains optimistic about its HIV portfolio. The company is preparing for the launch of lenacapavir, a long-acting PrEP medication, in the summer of 2025. Analysts expect this launch to remain robust, potentially offsetting some of the pressures faced by the existing HIV prevention products.

Yeztugo Coverage Challenges

One of the most recent developments for Gilead has been the decision by CVS Caremark to decline coverage for Yeztugo, a new HIV PrEP medicine. This decision, citing clinical, financial, and regulatory factors, has been viewed as an incremental negative for Gilead. However, the company remains confident in achieving its access goals for Yeztugo, targeting 75% access within six months and 90% within 12 months.

The CVS decision has sparked moderate investor feedback, with some viewing it as a small negative development. The focus now shifts to how other major players like UnitedHealth Group and Cigna will respond to Yeztugo’s formulation. Gilead’s management believes that the US Preventative Services Task Force (USPSTF) will eventually mandate coverage due to Yeztugo’s efficacy demonstrated in trials.

Oncology Portfolio: A Growth Driver

While facing headwinds in its HIV franchise, Gilead’s oncology portfolio is emerging as a promising growth driver. The company’s oncology segment, particularly led by Trodelvy and Cell therapies, has shown positive momentum. Analysts are optimistic about the potential of these products to contribute significantly to Gilead’s future revenue growth.

The expansion of Gilead’s oncology franchise is seen as a key factor in potentially driving multiple expansion for the stock. As the company continues to derisk this segment and demonstrate clinical and commercial success, it could help offset challenges faced in other areas of the business.

Market Outlook and Valuation

Gilead’s stock has shown resilience in the face of recent challenges, remaining one of the stronger performers in the healthcare sector. This performance is partly attributed to a broader market shift towards value-oriented investments, which has benefited Gilead.

Analysts at BMO Capital Markets have maintained an "Outperform" rating for Gilead, with a price target of $130. This target, based on a sum-of-the-parts discounted cash flow analysis with a 6.3% discount rate, represents a potential total return of 12% from the August 20, 2025 stock price.

Bear Case

How might reduced government funding affect Gilead’s HIV franchise?

The potential cuts to HHS funding for domestic HIV prevention could have a significant impact on Gilead’s PrEP franchise. Reduced community engagement and testing initiatives may slow revenue growth for certain products within the HIV portfolio. This could lead to a decrease in new patient starts and potentially affect the uptake of Gilead’s HIV prevention medications.

Furthermore, if government funding cuts result in fewer resources for HIV education and awareness programs, it could indirectly impact the demand for Gilead’s HIV products. The company may need to invest more in its own marketing and education efforts to maintain market share and growth in this segment.

Could challenges in gaining formulary coverage for Yeztugo impact overall revenue?

The decision by CVS Caremark to exclude Yeztugo from its formulary raises concerns about the drug’s market acceptance and potential revenue impact. If other major pharmacy benefit managers follow suit, it could significantly limit Yeztugo’s market penetration and revenue potential.

Moreover, the challenges in gaining commercial formulary placements may signal broader issues with the drug’s pricing strategy or perceived value proposition. This could lead to slower-than-expected uptake and potentially impact Gilead’s projected revenue from Yeztugo. The company may need to reassess its pricing and market access strategies to ensure broader coverage and adoption of the drug.

Bull Case

How could Gilead’s expanding oncology portfolio drive future growth?

Gilead’s oncology portfolio, particularly led by Trodelvy and Cell therapies, presents a significant opportunity for future growth. As these products gain traction in the market and potentially expand into new indications, they could become major revenue drivers for the company.

The oncology market is known for its high-value treatments and potential for blockbuster drugs. If Gilead can successfully leverage its research and development capabilities to bring innovative oncology therapies to market, it could significantly diversify its revenue streams and reduce dependence on the HIV franchise. This expansion could also lead to multiple expansion for Gilead’s stock as investors recognize the growth potential in this segment.

What potential does the upcoming lenacapavir launch hold for Gilead’s market position?

The launch of lenacapavir, a long-acting PrEP medication, in the summer of 2025 could be a game-changer for Gilead’s HIV prevention portfolio. As a bi-annual treatment, lenacapavir has the potential to improve patient adherence and convenience compared to daily oral therapies.

If successful, lenacapavir could strengthen Gilead’s leadership position in HIV prevention and potentially capture market share from competitors. The launch could also help offset any negative impacts from potential government funding cuts to HIV prevention programs. Moreover, the introduction of this innovative treatment could reinforce Gilead’s reputation as a pioneer in HIV therapeutics, potentially leading to increased investor confidence and stock appreciation.

SWOT Analysis

Strengths:

• Strong market position in HIV treatment and prevention
• Expanding oncology portfolio with promising products like Trodelvy
• Robust research and development capabilities
• Solid financial performance with consistent earnings beats

Weaknesses:

• Recent revenue miss in earnings report
• Challenges in gaining formulary coverage for new products like Yeztugo
• Dependence on HIV franchise for a significant portion of revenue

Opportunities:

• Upcoming launch of lenacapavir, a long-acting PrEP medication
• Potential for multiple expansion as oncology franchise derisks
• Growing market for innovative cancer treatments
• Possible expansion into new therapeutic areas

Threats:

• Potential government funding cuts for HIV prevention programs
• Increasing competition in both HIV and oncology markets
• Regulatory challenges and pricing pressures in key markets
• Risk of clinical trial failures or regulatory setbacks for pipeline products

Analysts Targets

• BMO Capital Markets: $130 (August 21st, 2025)
• BMO Capital Markets: $115 (March 19th, 2025)

This analysis is based on information available up to September 18, 2025.

InvestingPro: Smarter Decisions, Better Returns

Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on GILD. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore GILD’s full potential at InvestingPro.

Should you invest in GILD right now? Consider this first:

Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if GILD is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.

To evaluate GILD further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if GILD appears on our undervalued or overvalued stock lists.

These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.